Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial
Her background in metabolic strategy and women's health brings a thoughtful, holistic perspective to weight loss care combining medication with nutrition guidance and ongoing physician support
That and more news below
BMI emerged as the most critical determinant of eligibility disparities: using the standard BMI 30 kg/m 2 threshold for obesity trials, only 13.5% of Asian US adults and 7.2% of Korean adults would be eligible, compared with 41.5% of Non-Asian US adults
Henry Sobo notes
US$ 28.07
US$ 22.14
US$ 24.38
US$ 29.96
